Vericel Corp Ord (VCEL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vericel Corp Ord (VCEL) has a cash flow conversion efficiency ratio of 0.042x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($15.01 Million) by net assets ($354.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vericel Corp Ord - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Vericel Corp Ord's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Vericel Corp Ord balance sheet liabilities for a breakdown of total debt and financial obligations.
Vericel Corp Ord Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vericel Corp Ord ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Believe SAS
PA:BLV
|
0.049x |
|
Artivion Inc
NYSE:AORT
|
0.044x |
|
Horace Mann Educators Corporation
NYSE:HMN
|
0.102x |
|
Heineken Bhd
KLSE:3255
|
0.327x |
|
Sinomag Technology Co Ltd
SHE:300835
|
0.011x |
|
Veridis Environment Ltd
TA:VRDS
|
0.050x |
|
Amara Raja Batteries Limited
NSE:ARE&M
|
0.068x |
|
Anhui Xinhua Media Co Ltd
SHG:601801
|
-0.035x |
Annual Cash Flow Conversion Efficiency for Vericel Corp Ord (1995–2025)
The table below shows the annual cash flow conversion efficiency of Vericel Corp Ord from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Vericel Corp Ord worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $354.64 Million | $51.91 Million | 0.146x | -26.52% |
| 2024-12-31 | $291.97 Million | $58.16 Million | 0.199x | +27.47% |
| 2023-12-31 | $225.95 Million | $35.31 Million | 0.156x | +69.89% |
| 2022-12-31 | $192.27 Million | $17.69 Million | 0.092x | -46.00% |
| 2021-12-31 | $170.46 Million | $29.04 Million | 0.170x | +30.17% |
| 2020-12-31 | $134.26 Million | $17.57 Million | 0.131x | +302.42% |
| 2019-12-31 | $111.09 Million | $-7.18 Million | -0.065x | -1504.40% |
| 2018-12-31 | $102.23 Million | $-412.00K | -0.004x | +99.31% |
| 2017-12-31 | $22.54 Million | $-13.18 Million | -0.585x | +27.35% |
| 2016-12-31 | $24.71 Million | $-19.89 Million | -0.805x | -33.49% |
| 2015-12-31 | $22.13 Million | $-13.35 Million | -0.603x | +15.41% |
| 2014-12-31 | $35.64 Million | $-25.41 Million | -0.713x | +86.08% |
| 2013-12-31 | $3.89 Million | $-19.94 Million | -5.121x | -64.90% |
| 2012-12-31 | $9.51 Million | $-29.55 Million | -3.106x | -264.48% |
| 2011-12-31 | $-12.97 Million | $-24.49 Million | 1.888x | +136.58% |
| 2010-12-31 | $2.92 Million | $-15.09 Million | -5.163x | -546.36% |
| 2009-12-31 | $17.28 Million | $-13.80 Million | -0.799x | +4.56% |
| 2008-12-31 | $23.33 Million | $-19.53 Million | -0.837x | -59.46% |
| 2007-12-31 | $28.25 Million | $-14.83 Million | -0.525x | -64.38% |
| 2006-12-31 | $42.34 Million | $-13.52 Million | -0.319x | +4.70% |
| 2005-12-31 | $33.03 Million | $-11.06 Million | -0.335x | +38.07% |
| 2004-12-31 | $17.61 Million | $-9.53 Million | -0.541x | +30.35% |
| 2003-12-31 | $11.57 Million | $-8.99 Million | -0.777x | +4.10% |
| 2002-12-31 | $10.80 Million | $-8.75 Million | -0.810x | -38.68% |
| 2001-12-31 | $10.89 Million | $-6.36 Million | -0.584x | -5.60% |
| 2000-12-31 | $12.44 Million | $-6.88 Million | -0.553x | +57.97% |
| 1999-12-31 | $8.51 Million | $-11.20 Million | -1.316x | +8.75% |
| 1998-12-31 | $10.85 Million | $-15.64 Million | -1.442x | -103.97% |
| 1997-12-31 | $18.81 Million | $-13.30 Million | -0.707x | +11.77% |
| 1996-12-31 | $16.60 Million | $-13.30 Million | -0.801x | +57.74% |
| 1995-12-31 | $4.80 Million | $-9.10 Million | -1.896x | -- |
About Vericel Corp Ord
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the … Read more